Search results for "Lymphatic"

showing 10 items of 1179 documents

Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical canc…

2015

Objective: To investigate the feasibility and determine the recommended pre-operative intensity-modulated radiotherapy (IMRT) dose of extended-field chemoradiation along with simultaneous integrated boost (SIB) dose escalation. Methods: A radiation dose of 40Gy over 4 weeks, 2Gy/fraction, was delivered to the tumour and the lymphatic drainage (planning target volume, PTV3), which encompassed a volume larger than standard (common iliac lymphatic area up to its apex, in front of the L3 vertebra), concurrently with chemotherapy (cisplatin and 5-fluorouracil). Radiation dose was escalated to the pelvis (PTV2) and to the macroscopic disease (PTV1) with the SIB-IMRT strategy. Three dose levels we…

Chemoradiotherapy; Dose Fractionation; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Preoperative Period; Prospective Studies; Radiotherapy Dosage; Radiotherapy Planning Computer-Assisted; Radiotherapy Intensity-Modulated; Treatment Outcome; Uterine Cervical Neoplasms; Radiology Nuclear Medicine and Imaging; Medicine (all)Uterine Cervical NeoplasmRadiology Nuclear Medicine and Imagingcervical cancermedicine.medical_treatmentUterine Cervical NeoplasmsMedicineHumansProspective StudiesProspective cohort studyDose FractionationSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIANeoplasm StagingCervical cancerCisplatinChemotherapyFull Paperbusiness.industryMedicine (all)Radiotherapy Planning Computer-AssistedDose fractionationRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle Agedmedicine.diseaseRadiation therapyFeasibility StudieProspective StudieLymphatic systemTreatment OutcomePreoperative PeriodFeasibility StudiesFemaleDose Fractionation RadiationRadiotherapy Intensity-ModulatedbusinessNuclear medicineChemoradiotherapymedicine.drugHumanThe British journal of radiology
researchProduct

Pediatric Anaplastic Large Cell Lymphoma with Concomitant Involvement of Spine and Central Nervous System: A Case Report and Review of Literature

2021

Anaplastic large cell lymphoma (ALCL) is a histological subtype of non-Hodgkin lymphoma, largely characterized by anaplastic lymphoma kinase (ALK) positivity, resulting from the chromosomal translocation t(2;5). We report a pediatric case of ALK-positive ALCL with primary concomitant involvement of bone and central nervous system (CNS); thereafter, a literature review about pediatric primary bone and primary CNS ALCL was conducted. According to the analyzed data, our case is unique because it is characterized by the contemporary involvement of the spine and CNS. During and after chemotherapy, our patient was monitored by detecting minimal residual disease (MRD) through the analysis of fusio…

ChemotherapyPathologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentRcentral nervous systemmedicine.diseaseboneMinimal residual diseaseLymphomamedicine.anatomical_structureFusion transcriptanaplastic large cell lymphomahemic and lymphatic diseasesConcomitantminimal residual diseasemedicineMedicineAnaplastic lymphoma kinaseBone marrowbusinessAnaplastic large-cell lymphomaHemato
researchProduct

Clinical Course and Significance of the Novel FLT3-Y842C Mutation in a Patient with AML Treated with PKC412 Monotherapy.

2004

Abstract We recently identified a novel mutation (Y842C) within the tyrosine kinase domain of FLT3 in a patient treated with PKC410 monotherapy (ASH 2003, # 4681). Here, we present follow up studies including the clinical course of the patient and frequency analysis in 110 patients with AML. In addition, we characterized the novel mutation using overexpression of FLT3-Y842C in 32D cells. AML M2 was diagnosed in a 63 year old, male patient in 1993. After having experienced his second relapse upon standard therapy the patient was refractory to alemtuzumab treatment. Due to reduced performance status the patient was not eligible to standard chemotherapy and was enrolled into a phase II trial i…

ChemotherapyPerformance statusbusiness.industryPoint mutationmedicine.medical_treatmentImmunologyhemic and immune systemsCell BiologyHematologyBioinformaticsBiochemistryExonfluids and secretionshemic and lymphatic diseasesembryonic structuresCancer researchmedicineAlemtuzumabClinical significancebusinessTyrosine kinaseEx vivomedicine.drugBlood
researchProduct

Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32

2010

To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study. We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 × 10-29 and rs7755224, combined P = 2.00 × 10-19; r2 = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility. We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 × 10-9). © 2010 Nature America, Inc. All rights reserved.

Chronic lymphocytic leukemiaFollicular lymphomaLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyArticleMajor Histocompatibility Complex03 medical and health sciences0302 clinical medicinefollicular lymphomaRisk Factorshemic and lymphatic diseasesGeneticsmedicineHumansLymphoma Follicular030304 developmental biology0303 health sciencesLymphoma Non-HodgkinGenetic Variation16. Peace & justicemedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good healthLymphomaNon-Hodgkin's lymphomaLeukemia030220 oncology & carcinogenesisImmunologyDisease SusceptibilityGenome-Wide Association Study
researchProduct

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome

2010

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma. Risk factors of CLL transformation to RS are only partly known. We explored the role of the host genetic background as a risk factor for RS occurrence. Forty-five single nucleotide polimorphisms (SNPs) known to be relevant for CLL prognosis were genotyped in a consecutive cohort of 331 CLL, of which 21 had transformed to RS. After correcting for multiple testing and adjusting for previously reported RS risk factors, the LRP4 rs2306029 TT variant genotype was the sole SNP independently associated with a higher risk of RS transformation (Hazard Ratio: 4·17; P = 0·001; q = 0·047).…

Chronic lymphocytic leukemiaSingle-nucleotide polymorphismAggressive lymphomaHematologyBiologymedicine.diseasehemic and lymphatic diseasesImmunologyGenotypemedicineSNPRisk factorGenotypingDiffuse large B-cell lymphomaBritish Journal of Haematology
researchProduct

El sistema linfático: el gran olvidado del sistema circulatorio.

2014

En el presente artículo se analizan los modelos mentales y las concepciones alternativas que tienen los estudiantes de distintos niveles educativos sobre el sistema linfático como componente del sistema circulatorio. Se establece una relación con las dificultades que se salvaron a lo largo de la historia en la adquisición de dichos conocimientos. Los resultados muestran una deficiente relación entre los sistemas linfáticos y sanguíneos, una falta de conocimientos tanto anatómicos como fisiológicos del sistema linfático y una dificultad para ampliar el modelo explicativo del transporte de nutrientes en los organismos animales, exclusivamente centrado en el sistema sanguíneo. Se termina ofrec…

Ciències naturalsalternative conceptionsSocial Sciencesconcepciones alternativaslymphatic systemcirculatory deviceEducació InvestigacióEducationCiència EnsenyamentHlinfalymphmodelos mentalessistema circulatoriosistema linfáticoSistema cardiovascular
researchProduct

Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives.

2014

STATs are transcription factors acting as intracellular signaling after stimulation with cytokines, growth factors and hormones. STAT5 is also constitutively active in many forms of cancers, including chronic myelogenous leukemia, acute lymphoblastic leukemia and Hodgkin's lymphoma. Recently, literature reported that the neuroleptic drug pimozide inhibits STAT5 phosphorylation inducing apoptosis in CML cells. We undertook an investigation from pimozide structure, obtaining simple derivatives with cytotoxic and STAT5-inhibitory activity, two of them markedly more potent than pimozide.

Clinical BiochemistryFusion Proteins bcr-ablPharmaceutical ScienceApoptosisBiochemistrySettore MED/15 - Malattie Del SangueCell LineStructure-Activity RelationshipPimozideSettore BIO/13 - Biologia Applicatahemic and lymphatic diseasesDrug DiscoverymedicineSTAT5 Transcription FactorCytotoxic T cellHumansPhosphorylationMolecular BiologyTranscription factorSTAT5Cell ProliferationbiologyDose-Response Relationship DrugMolecular StructureChemistrySTAT5 inhibitorsPimozideBCR/ABL expressing leukemia ApoptosisCell growth inhibitionOrganic ChemistryCell CyclePimozidemedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaLeukemiaApoptosisCancer researchbiology.proteinSettore BIO/14 - FarmacologiaMolecular MedicinePhosphorylationK562 Cellsmedicine.drugChronic myelogenous leukemia
researchProduct

Evaluation of Clotting Factor Concentrates for Treatment of Thrombotic Thrombocytopenic Purpura.

2010

Abstract Abstract 3678 Introduction: Thrombotic thrombocytopenic purpura (TTP) is characterized by microthrombi, hemolytic anemia as well as thrombocytopenia. These symptoms are caused by a decreased activity of the protease ADAMTS13 which cleaves the von Willebrand Factor (VWF), due to mutation of the ADAMTS13-gene or autoantibodies. At the moment, the only available immediate therapy is plasmapheresis with Fresh Frozen Plasma (FFP) which may induce side effects. Therefore an alternative therapy might be the treatment with clotting factor concentrates. Methods: 40 plasma samples were tested, consisting of FFP and solvent/detergent treated plasma, four batches of each blood group; VWF/VIII …

Clotting factorHemolytic anemiamedicine.medical_specialtybiologyChemistrymedicine.medical_treatmentImmunologyAutoantibodyThrombotic thrombocytopenic purpuraCell BiologyHematologymedicine.diseaseBiochemistryADAMTS13EndocrinologyVon Willebrand factorhemic and lymphatic diseasesInternal medicineImmunologymedicinebiology.proteinPlasmapheresisFresh frozen plasmaBlood
researchProduct

Vascular Microarchitecture of Murine Colitis-Associated Lymphoid Angiogenesis

2009

In permissive tissues, such as the gut and synovium, chronic inflammation can result in the ectopic development of anatomic structures that resemble lymph nodes. These inflammation-induced structures, termed lymphoid neogenesis or tertiary lymphoid organs, may reflect differential stromal responsiveness to the process of lymphoid neogenesis. To investigate the structural reorganization of the microcirculation involved in colonic lymphoid neogenesis, we studied a murine model of dextran sodium sulfate (DSS)-induced colitis. Standard 2-dimensional histology demonstrated both submucosal and intramucosal lymphoid structures in DSS-induced colitis. A spatial frequency analysis of serial histolog…

Colitis LymphocyticPathologymedicine.medical_specialtyHistologyStromal cellLymphoid TissueAngiogenesisBiologyArticleMicrocirculationMicemedicineAnimalsIntestinal MucosaColoring AgentsEcology Evolution Behavior and SystematicsMicrodissectionMicroscopy ConfocalNeovascularization PathologicStaining and LabelingMicrocirculationDextran SulfateHistologyMatrix MetalloproteinasesCapillariesMice Inbred C57BLDisease Models AnimalLymphatic systemRegional Blood FlowCytokinesLymphChemokinesAnatomyIntravital microscopyBiotechnologyThe Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology
researchProduct

Fluorescent Sensing of Maleate versus Fumarate by a Neutral Cyclohexane Based Thiourea Receptor.

2006

A new cyclohexyl based fluorescent anion receptor, is able to recognize maleate versus fumarate both as their TMA salts. Costero Nieto, Ana Maria, Ana.Costero@uv.es ; Colera Llavata, Manuel, Manuel.Colera@uv.es ; Gaviña Costero, Pablo, Pablo.Gavina@uv.es ; Gil Grau, Salvador, Salvador.Gil@uv.es

CyclohexaneUNESCO::QUÍMICAurologic and male genital diseases:QUÍMICA [UNESCO]Medicinal chemistryCatalysischemistry.chemical_compoundhemic and lymphatic diseasesNeutral cyclohexaneMaterials ChemistryFluorescentOrganic chemistryUNESCO::QUÍMICA::Química orgánicaReceptorneoplasmsAnion receptorThiourea receptorFumarateMaleate:QUÍMICA::Química orgánica [UNESCO]Metals and AlloysGeneral ChemistryGeneral MedicineFluorescenceSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsFluorescent ; Neutral cyclohexane ; Thiourea receptor ; Maleate ; FumarateThioureachemistryCeramics and CompositesChemInform
researchProduct